Sionna Therapeutics is betting that two correctors working on different parts of the CFTR protein will accomplish what one cannot: meaningful sweat chloride reduction in patients whose disease persists despite Trikafta. The company announced plans to advance SION-451 and SION-2222 together into a Phase 2a proof-of-concept trial, a decision driven by post hoc data from the PreciSION CF study of its earlier compound, SION-719.
That data showed a mean placebo-adjusted sweat chloride reduction of up to 8.6 mmol/L in a subset of patients, attributed to SION-719’s activity at nucleotide binding domain 1 (NBD1). The result is modest on its own, but Sionna’s argument is mechanistic: SION-451 targets NBD1 stabilization while SION-2222 acts elsewhere on the corrector pathway, and the two together are designed to produce additive correction that neither achieves alone. Whether that logic holds in a prospectively designed trial is exactly what the Phase 2a will test.
The strategic context matters here. Ivacaftor’s 2012 approval proved that targeting CFTR function directly could transform CF care, and Trikafta extended that benefit to the large F508del population after its 2019 approval. But a subset of patients on existing modulators still carry residual disease burden, and Sionna is positioning its NBD1 program as a potential add-on for that group rather than a replacement for the current standard. That framing shapes everything about the trial design: success means demonstrating incremental biology on top of Trikafta, not competing head-to-head with it.
The critical number to watch when Phase 2a data emerge will not be whether sweat chloride moves at all, but by how much it moves beyond what the PreciSION subset showed. Eight-point-six mmol/L from a post hoc analysis in a small group is a biological signal, not a clinical threshold. Regulators and investors will want to see whether a prospectively enrolled, dual-combination cohort can reproduce and extend that reduction consistently enough to justify later-stage investment.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
